Posts From June, 2012

Combination therapy offers improved visual outcome compared with anti-VEGF monotherapy, trial finds

“Use of a novel anti-platelet-derived growth factor therapy in concert with ranibizumab resulted in a statistically significant improvement in visual outcome vs. ranibizumab monotherapy for the treatment of wet age-related macular degeneration, according to a press release from Ophthotech…” Retinal Consultants of AZ is committed to clinical research and the pursuit of new and improved… Read More »


Anti-PDGF Combination Agent More Effective Than Ranibizumab Monotherapy for Wet AMD

“The anti-platelet derived growth factor (PDGF) combination agent Fovista (Ophthotech Corp.) showed statistically significant superior efficacy over ranibizumab (Lucentis, Genentech) monotherapy for the treatment of wet AMD, according to the results of a phase 2b study, which were recently reported in an Ophthotech release…” Retinal Consultants of AZ is committed to clinical research and the… Read More »